178% Intraday Surge: This US Biopharma Stock Skyrockets After Eye Disease Drug Clears Key Hurdle
NDTV Profit · 28 September 2026

Kodiak said the completion of five successful Phase 3 trials positions the company to submit the treatments for US Food and Drug Administration approval later this year.
Full story published by NDTV Profit. Namaste Indian aggregates India headlines so you can discover and discuss them with people across every state.
Related articles
- Coforge Appoints Akhil Gupta As Chairperson Days After Key Board Exits
NDTV Profit
- Ola Electric Board Approves Rights Issue Of Up To Rs 1,000 Crore; Promoter To Participate
NDTV Profit
- Lupin gets U.S. FDA tentative nod for Apixaban Oral Suspension
The Hindu
- Jio Gains 2.4 Million Mobile Users In August, Airtel 2.1 Million: TRAI Data
NDTV Profit
- Facebook Marketplace Mishap: Meta User Says Muse AI Gave Out His Address, Agreed To Pickup He Never Approved
NDTV Profit
- Trump Faces US Midterm Defeat? Iran War, Immigration Drive To Cost Him Polls | Vantage
Firstpost